ANDA 203367, held by Aurobindo Pharma. Pravastatin Sodium.
As of Nov 16, 2026, ANDA 203367 (Pravastatin Sodium), held by Aurobindo Pharma, was first approved by FDA on Feb 2, 2017, with 3 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 2, 2017 | Original application | Approved | None posted |
| Pravastatin Sodium10MG · tablet;oral | Pravastatin Sodium | Rx |
| Pravastatin Sodium20MG · tablet;oral | Pravastatin Sodium | Rx |
| Pravastatin Sodium40MG · tablet;oral | Pravastatin Sodium | Rx |
| Pravastatin Sodium80MG · tablet;oral | Pravastatin Sodium | Rx |
| Mar 18, 2025 | Supplement 9Labeling · Standard review | Approved | None posted |
| Apr 13, 2023 | Supplement 7Labeling · Standard review | Approved | None posted |
| Mar 15, 2021 | Supplement 5Labeling · Standard review | Approved | None posted |
| Feb 2, 2017 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters